Hasil Pencarian - Patricia A. Culp

  • Menampilkan 1 - 5 hasil dari 5
Perbaiki Hasil
  1. 1
    CRISPR/Cas9 disruption of EpCAM Exon 2 results in cell-surface expression of a truncated protein targeted by an EpCAM specific T cell engager

    CRISPR/Cas9 disruption of EpCAM Exon 2 results in cell-surface expression of a truncated protein targeted by an EpCAM specific T cell engager oleh Andisheh Bagheri, Patricia A. Culp, Robert B. DuBridge, Tseng-hui Timothy Chen

    Diterbitkan 2022-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells

    Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells oleh Shiming Ye, Melvin I. Fox, Nicole A. Belmar, Mien Sho, Debra T. Chao, Donghee Choi, Yuni Fang, Vivian Zhao, Stephen F. Keller, Gary C. Starling, Patricia A. Culp

    Diterbitkan 2017-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Nuclear Factor κB is required for tumor growth inhibition mediated by enavatuzumab (PDL192), a humanized monoclonal antibody to TweakR

    Nuclear Factor κB is required for tumor growth inhibition mediated by enavatuzumab (PDL192), a humanized monoclonal antibody to TweakR oleh James W. Purcell, Han K. Kim, Sonia G. Tanlimco, Minhtam eDoan, Melvin eFox, Peter eLambert, Debra T. Chao, Mien eSho, Keith E. Wilson, Gary C. Starling, Gary C. Starling, Patricia A. Culp

    Diterbitkan 2014-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenografts.

    Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenografts. oleh Ludmilla de Plater, Anne Vincent-Salomon, Frédérique Berger, André Nicolas, Sophie Vacher, Eléonore Gravier, Aurélie Thuleau, Narjesse Karboul, Marion Richardson, Clément Elbaz, Elisabetta Marangoni, Ivan Bièche, Xavier Paoletti, Sergio Roman-Roman, Patricia A Culp, Bernard Asselain, Véronique Diéras, Didier Decaudin

    Diterbitkan 2014-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    COBRA™: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors

    COBRA™: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors oleh Anand Panchal, Pui Seto, Russell Wall, Brian J. Hillier, Ying Zhu, Jessica Krakow, Aakash Datt, Elizabeth Pongo, Andisheh Bagheri, Tseng-Hui T. Chen, Jeremiah D. Degenhardt, Patricia A. Culp, Danielle E. Dettling, Maia V. Vinogradova, Chad May, Robert B. DuBridge

    Diterbitkan 2020-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: